Friday, 17 Nov 2017

You are here

FDA Approves Tremfya (guselkumab) for Plaque Psoriasis

The U.S. Food and Drug Administration (FDA) has approved the IL-23 inhibitor, Tremfya (guselkumab), for patients with moderate to severe plaque psoriasis.

The drug received an expedited regulatory review following application of an FDA Priority Review Voucher.

After loading doses at weeks 0 and 4, guselkumab is given as 100 mg subcutaneously (prefilled syringe) every eight weeks. In clinical studies, patients receiving Tremfya experienced significant improvement in skin clearance and greater improvement in symptoms of plaque psoriasis including itch, pain, stinging, burning and skin tightness when compared with placebo at week 16.

The clinical development program included more than 2,000 patients in the Phase 3 VOYAGE 1, VOYAGE 2 and NAVIGATE studies, which have been previously presented or published in peer-reviewed journals. In a head-to-head trial, guselkumab beat adalimumab (ADA) with PASI90 results of 73% compted to 2.9% on placebo and 50% percent on ADA.

The NAVIGATE study tested the effectiveness of Tremfya in patients who had an inadequate response to ustekinumab and found 28-31% of Tremfya-treated patients were considered cleared or almost cleared versus 14% of UST treated patients at 12 weeks.

There are no contraindications or boxed warnings. Most common (≥1%) adverse reactions associated with Tremfya include upper respiratory infections, headache, injection site reactions, arthralgia,diarrhea, gastroenteritis, tinea infections, and herpes simplex infections. Elevated hepatic enzymeswere reported more frequently in the Tremfya group (2.6%) than in the placebo patients (1.9%). 

Guselkumab has been shown to be ineffective in rheumatoid arthritis, and is currently under study in psoriatic arthritis and ankylosing spondylitis. 

The addition of Tremfya will crowd a growing market for psoriatic therapies and will compete with existing approve therapies including the TNF inhibitiors, the IL-17 inhibitors (secukinumab, ixekizumab) and apremilast. Next month, the FDA will convene a hearing over the application to approve tofacitinib for psoriatic arthritis.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

MTX Doubles Hepatotoxicity Risk in Psoriasis Patients

A study from the University of Pennsylvania Perelman School of Medicine was published in the Journal of Investigative Dermatology showing that the risk of incident liver disease doubled when patients with psoriasis (PsO) or psoriatic arthritis (PsA) take methotrexate (MTX), but not when MTX is used in rheumatoid arthritis. (Citation source https://buff.ly/2i9qizC)

Several Agents Score on Radiographic Progression in Psoriatic Arthritis

Reduction on radiographic progression has now become the standard of care in the therapies used to treat psoriatic arthritis and, during the 2017 ACR Meeting, several agents reported the results of their studies with radiographic endpoints.

IL-17 Inhibition with Secukinumab in PsA: X-Ray Outcomes

With the emergence of new MOAs for the treatment of psoriatic arthritis in recent years, the most burning question remained if newer agents would perform as well in terms of radiographic progression as they did in clinical domains.

Novartis Features Secukinumab Data at ACR 17

Novartis has announce it will present its long-term 4-year data in ankylosing spondylitis (AS) and 24-weeks data in psoriatic arthritis (PsA) to be presented at the 2017 ACR/ARHP Annual Meeting

Structural disease progression is a major concern for AS and PsA patients as it may prompt mobility loss - new data to provide further evidence on the efficacy of Cosentyx to reduce structural disease progression.

FDA Approves Simponi Aria for Psoriatic Arthritis and Ankylosing Spondylitis

Janssen Biotech, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved SIMPONI ARIA® (golimumab) the treatment of adults with active psoriatic arthritis (PsA) or active ankylosing spondylitis (AS).